GGrantIndex
← Leaderboards

Steven M Hersch

Emory University

Google Scholar ↗PubMed ↗ORCID ↗
$23,995,705
Attributed
$28,222,037
Total exposure
11
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.5M · FY2005–18
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$40,052,738 · 12
FDA$1,049,922 · 1

By mechanism

U01$16,260,798 · 2
P01$14,399,281 · 6
U44$5,635,109 · 1
R01$4,792,539 · 3
M01$14,933 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Creatine”

Research focus

CreatineClinical ResearchHuntington DiseaseSymptomsProgramsBrainBaseResponseDoseNeuropathologyPhenotypeMeetingsClinical TrialsHuman SubjectOxidative StressHuntington'S DiseasePre-ClinicalFutureMetabolomicsPrincipal InvestigatorDisease ProgressionDietary SupplementsDouble-Blind MethodRandomized

Grant awards (54)

Tolerability of SRX246 in Huntington's Disease Patients$764,163
U44 · FY2018 · NS
Tolerability of SRX246 in Huntington's Disease Patients$1,480,173
U44 · FY2017 · NS
Tolerability of SRX246 in Huntington's Disease Patients$61,234
U44 · FY2017 · NS
Tolerability of SRX246 in Huntington's Disease Patients$2,214,354
U44 · FY2016 · NS
Tolerability of SRX246 in Huntington's Disease Patients$1,115,185
U44 · FY2015 · NS
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$411,170
U01 · FY2015 · AT · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$1,500,000
U01 · FY2014 · AT · contact PI
Blood Level of Huntingtin: A Biomarker for Huntington's Disease$681,744
U01 · FY2014 · NS · contact PI
Blood Level of Huntingtin: A Biomarker for Huntington's Disease$663,721
U01 · FY2013 · NS · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$500,000
U01 · FY2013 · AT · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$1,285,098
P01 · FY2012 · NS · contact PI
Blood Level of Huntingtin: A Biomarker for Huntington's Disease$695,125
U01 · FY2012 · NS · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$667,289
U01 · FY2012 · AT · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$1,285,251
P01 · FY2011 · NS · contact PI
Blood Level of Huntingtin: A Biomarker for Huntington's Disease$684,982
U01 · FY2011 · NS · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$40,884
P01 · FY2011 · NS · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$2,241,672
U01 · FY2010 · AT · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$1,279,832
P01 · FY2010 · NS · contact PI
Blood Level of Huntingtin: A Biomarker for Huntington's Disease$664,675
U01 · FY2010 · NS · contact PI
CREATINE THERAPY TO TREAT HUNTINGTON'S DISEASE: A PHASE 3 STUDY$349,974
R01 · FY2010 · FD · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$2,264,317
U01 · FY2009 · AT · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$1,291,764
P01 · FY2009 · NS · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$591,961
U01 · FY2009 · AT · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$2,264,317
U01 · FY2008 · AT · contact PI
Biomarkers for Huntington's Disease: Accelerating the Development of Therapies$1,384,080
P01 · FY2008 · NS · contact PI
CREATINE THERAPY TO TREAT HUNTINGTON'S DISEASE: A PHASE 3 STUDY$349,974
R01 · FY2008 · FD · contact PI
Administrative and Analytic Core$209,676
P01 · FY2008 · NS · contact PI
Biomarkers and Creatine Therapy in Presymptomatic HD$191,945
P01 · FY2008 · NS · contact PI
Clinical Core$71,868
P01 · FY2008 · NS · contact PI
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E$2,429,825
U01 · FY2007 · AT · contact PI
Transcription and Therapy for HD: from Molecules to Man$1,205,445
P01 · FY2007 · NS · contact PI
CREATINE THERAPY TO TREAT HUNTINGTON'S DISEASE: A PHASE 3 STUDY$349,974
R01 · FY2007 · FD · contact PI
Chemotherapy for Huntington's Disease$200,908
P01 · FY2007 · NS · contact PI
Transcription and Therapy for HD: from Molecules to Man$1,233,746
P01 · FY2006 · NS · contact PI
Chemotherapy for Huntington's Disease$210,572
P01 · FY2006 · NS · contact PI
Transcription and Therapy for HD: from Molecules to Man$1,249,142
P01 · FY2005 · NS
Chemotherapy for Huntington's Disease$208,189
P01 · FY2005 · NS
Transcription and Therapy for HD: from Molecules to Man$1,248,267
P01 · FY2004 · NS
Creatine Therapy for Huntington's Disease$420,848
R01 · FY2004 · AT
Chemotherapy for Huntington's Disease$208,044
P01 · FY2004 · NS
CREATINE SAFETY AND TOLERABILITY IN HUNTINGTON'S DISEASE (CREST-HD)$14,933
M01 · FY2004 · RR
Transcription and Therapy for HD: from Molecules to Man$1,304,739
P01 · FY2003 · NS
HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION$427,811
R01 · FY2003 · NS
Creatine Therapy for Huntington's Disease$410,854
R01 · FY2003 · AT
Chemotherapy for Huntington's Disease$217,456
P01 · FY2003 · NS
Creatine Therapy for Huntington's Disease$215,556
R01 · FY2003 · AT
Transcription and Therapy for HD: from Molecules to Man$72,375
P01 · FY2003 · NS
Creatine Therapy for Huntington's Disease$404,647
R01 · FY2002 · AT
HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION$341,624
R01 · FY2002 · NS
Creatine Therapy for Huntington's Disease$416,280
R01 · FY2001 · AT
HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION$333,262
R01 · FY2001 · NS
HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION$401,173
R01 · FY2000 · NS
Creatine Therapy for Huntington's Disease$320,562
R01 · FY2000 · AT
HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION$50,000
R01 · FY2000 · NS